Meloxicam, a small molecule drug, is a COX-2 inhibitor that targets the enzyme causing inflammation and pain.

Scholar Rock Reveals U.S. FDA Approval for Phase 2 Trial Commencement, Testing Apitegromab for Obesity Management.

Cyclobenzaprine is a drug opposing ADRA2, 5-HT2A, and H1 receptors, approved to treat muscle spasticity, fibromyalgia, stress disorders, back pain, and both active and post-COVID-19 symptoms.

Gabapentin is a small molecule drug developed by Pfizer that functions as a CACNA2D2 and Cav2.2 blocker.

Sanofi intends to buy Inhibrx, Inc., bringing a promising rare disease candidate targeting Alpha-1 Antitrypsin Deficiency into its portfolio.

Strand Therapeutics recently revealed that the FDA has approved its request to commence a Phase 1 clinical trial, marking the initial human study of STX-001.

Gilead Sciences' EVOKE-01 Phase 3 Trial for Metastatic NSCLC Fails to Achieve Primary Endpoint: A Comparison of Trodelvy and Docetaxel.

Sandoz Finalizes USD 170 Million Purchase of Coherus BioSciences' Biosimilar Drug CIMERLI* (ranibizumab-eqrn) in the US

BioNTech and DualityBio have launched a critical Phase 3 study for their therapeutic agent BNT323/DB-1303, targeting advanced breast cancer.

NK CellTech has received the green light from the Food and Drug Administration (FDA) to initiate clinical trials for its therapy, NK010.

ProMIS Neurosciences Inc. has declared the identification of a premier vaccine contender, PMN400.

AC Immune SA to Reclaim Global Ownership of Two Therapeutic Antibodies Post-Partnership with Genentech and Roche.